Head & neck
-
Randomized Controlled Trial
Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141).
The present study evaluated the 2-year survival of the Asian population in the CheckMate 141 trial. ⋯ NCT02105636.